CEA Testing Market

Carcinoembryonic antigen (CEA) is a protein usually produced in the developing fetus and disappears or is absent in adults. Abnormal amounts of this protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein is 0 micrograms to 0.25 micrograms per liter. Elevated levels of CEA in the patients recently treated for cancer, indicates recurrence of the cancer.

These elevated levels are attributed to different types of cancers and other conditions such as cholecystitis, lung infection, heavy smoking, inflammatory bowel diseases, peptic ulcer, etc. High levels of CEA are also found in the patients who are not diagnosed with cancer which might increase the risk of acquiring cancer. Hematoma (blood accumulating under the skin), infection, dizziness and excessive bleeding are some of the risks associated with abnormal levels of CEA. The abnormal levels of CEA in the body can be detected by using arcitumomab a monoclonal antibody; these are commonly used in the identification of glycoprotein expression in tissue samples.

The continuous technological advances followed by discovery of specific antigens, biomarkers, and etc. form the prime reason for tremendous growth of CEA testing market. The market can be segmented by instrumentation and on the basis of number of tests performed in specific geographies elucidating the market by volume and geography. Qualitative analysis of the regulatory policies and patent protection can highlight the need of CEA testing market.

The major factors influencing the growth of the market are rise in geriatric population, technological breakthroughs that aids in revealing the genetic basis of the disease, increased accuracy of the diagnostic procedures and rigorous research and development initiatives. Lack of awareness and availability of novel technological solutions might pose a challenge to the growth of CEA testing market. The companies competing in this market are Abbott Laboratories, Siemens Healthcare, bioMerieux, Danaher Corporation (Beckman Coulter), Myriad Genetics, Epigenomics, Qiagen N.V., and Life Technologies Corporation.

CEA ( carcinoembryonic antigen) test involves the process of measuring specific blood glycoprotein which is known as CEA.CEA is a protein that contains a lot of sugar. The abnormal growth of these cells can also cause cancer. High levels of CEA can cause severe health conditions such as lung infection, inflammatory bowel diseases, cholecystitis, peptic ulcer, and others. Concurrently, the cancerous effects of the elevated levels of CEA cannot be overlooked. Other than these ailments, it also causes hematoma, a medical condition in which blood accumulates under the skin. Dizziness, excessive bleeding, and infections are closely related to the rise in CEA levels. On the back of increasing health risks owing to the escalating levels of CEA, the CEA testing market is prognosticated to replenish good revenue to the CEA testing market.

Cancer spreads very quickly and poses a high risk. In case, the disease is diagnosed in the initial stages it can be treated effectively. Hence, the CEA testing is very important. Concurrently, the awareness of early detection of cancer has proved to be a growth booster for the CEA testing market. Health organizations and NGOs are taking initiatives to create awareness among the population regarding the early diagnosis and treatment of cancer. The knowledge regarding various tests that can be conducted in case of any symptoms is imparted to the masses. Also, the fear regarding the disease is eliminated through sharing of life experiences of patients who have completely recovered. The cancer survivors help in building courage among the people and give them the confidence that cancer can be cured completely if diagnosed at an early stage. All these developments have created unprecedented growth opportunities for the CEA testing market.

High prevalence of cancer across the globe has created a pressing need for developing accurate ergonomic and cost-effective testing methods which have eventually boosted the growth of the CEA testing market. The technological advancements in the CEA testing procedures have proved to be a boon for the healthcare sector. Consequently, the government bodies of various countries across the globe are focusing on developing the healthcare infrastructure and providing technologically advanced healthcare services to the masses. The advancements in the healthcare system through the adoption of cloud-based technologies and IoT have improved the testing procedures and made the diagnosis accurate and quick. Inferring to these developments the CEA testing market is expected to change the market dynamics in the coming years.